Azithromycin Treatment for the Airway Microbiome in Asthma
The AZITRAMBA Trial: Azithromycin Treatment for the Airway Microbiome in Asthma
Sponsor: Northwestern University
Terminated
Inability to accrue patients, particularly after COVID pandemic.
This PHASE2 trial investigates Asthma Chronic and is currently terminated or withdrawn. Northwestern University leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Dec 2021 — Sep 2023 [monthly]
Active Not Recruiting PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
▶ Show 8 earlier versions
-
Oct 2021 — Nov 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
May 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Northwestern University
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .